| (1) Responsibility and confidence in initiation and ongoing management of NOACs | |
| Q1 Are you responsible for starting/initiating and/or managing anticoagulation therapy? Please select the one answer that applies: | a) Starting/initiating b) Managing c) Both |
| Q2 Do you feel confident in starting/initiating NOAC therapy in appropriate patients? | a) Yes b) No (with reasons for not being confident) |
| Q3 Do you feel confident in managing their ongoing care? | a) Yes b) No (with reasons for not being confident) |
| Q4 Who in your multidisciplinary team do you work closely with to manage anticoagulation therapy in your patients? | a) Cardiologist b) Neurologist c) Haematologist d) Internist d) Vascular physician e) Warfarin/anticoagulation clinic staff f) Nurse practitioner g) Pharmacist |
| (2) Familiarity with AF stroke guidelines on NOACs use and anticoagulant switching | |
| Q5 Which of the following guidelines do you apply to the clinical management of your patients with atrial fibrillation? | a) European Society of Cardiology guidelines 2016 b) European Heart Rhythm Association guidelines 2015 c) American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines 2014 d) European Primary Care Cardiovascular Society guidelines 2015 e) Local/national atrial fibrillation management guidelines f) No specific guideline |
| Q6 What are the most common triggers for switching patients from a VKA (for example, warfarin) to a NOAC when clinically appropriate? | a) The burden of routine anticoagulation monitoring b) VKA adverse event c) Time in therapeutic range >70% d) Potential risk of VKA adverse event e) Patient preference f) Thrombotic event during VKA therapy g) Risk of discontinuation h) None of the above |
| Q7 From your experience, who is involved in switching patients from VKA therapy to a NOAC? | a) The PCP decides b) The PCP must refer to a specialist to switch c) Switching can happen at a thrombosis centre /anticoagulation clinic d) National resource allocator/market access decision maker is involved in the decision to switch e) None of the above |
| (3) Perceived information needs | |
| Q8 Are you interested in learning more about when or how to initiate anticoagulation therapy (NOACs or VKA), or its ongoing management? | a) Ongoing management of anticoagulation therapy b) When to initiate anticoagulation therapy c) How to initiate anticoagulation therapy d) None of the above |
| Q9 Which of the following topics do you feel is important to increase your knowledge, on a scale of 1-5 (where 1 = least important and 5 = very important) | a) The role of the primary care physician in the ongoing management of patients receiving NOACs b) The role of the primary care physician in prescribing NOACs c) The role of the anticoagulation clinic/thrombosis centre in the ongoing management of NOACs d) The role of the anticoagulation clinic/thrombosis centre in prescribing NOACs |
| Q10 Which of the following statements do you agree with when trying to find information about anticoagulation therapy? | a) Limited information on economic comparisons of the various anticoagulation therapies b) Lack of up-to-date real-world data c) Lack of adequate information from national scientific societies d) Lack of up-to-date clinical data e) Lack of adequate information from the pharmaceutical industry |
AF = atrial fibrillation. NOAC = non-vitamin K oral anticoagulant. VKA = vitamin K antagonist.